Drug Profile
Research programme: diabetes/obesity therapy - Benitec/The Garvan Institute of Medical Research
Latest Information Update: 18 Sep 2007
Price :
$50
*
At a glance
- Originator Benitec Ltd
- Class Small interfering RNA
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 14 Feb 2005 Preclinical trials in Diabetes mellitus in Australia (unspecified route)
- 14 Feb 2005 Preclinical trials in Obesity in Australia (unspecified route)